Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505) - Net Assets

Latest as of September 2025: CN¥2.26 Billion CNY ≈ $330.53 Million USD

Based on the latest financial reports, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505) has net assets worth CN¥2.26 Billion CNY (≈ $330.53 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.47 Billion ≈ $360.83 Million USD) and total liabilities (CN¥207.05 Million ≈ $30.30 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 688505 asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥2.26 Billion
% of Total Assets 91.6%
Annual Growth Rate 16.64%
5-Year Change 14.78%
10-Year Change 201.01%
Growth Volatility 43.36

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd - Net Assets Trend (2005–2024)

This chart illustrates how Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Shanghai Fudan-Zhangjiang Bio-Pharmaceut (688505) total assets for the complete picture of this company's asset base.

Annual Net Assets for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (2005–2024)

The table below shows the annual net assets of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd from 2005 to 2024. For live valuation and market cap data, see 688505 market cap.

Year Net Assets Change
2024-12-31 CN¥2.31 Billion
≈ $337.33 Million		 -2.26%
2023-12-31 CN¥2.36 Billion
≈ $345.13 Million		 +4.68%
2022-12-31 CN¥2.25 Billion
≈ $329.69 Million		 +2.90%
2021-12-31 CN¥2.19 Billion
≈ $320.41 Million		 +9.02%
2020-12-31 CN¥2.01 Billion
≈ $293.91 Million		 +115.24%
2019-12-31 CN¥933.15 Million
≈ $136.55 Million		 -6.05%
2018-12-31 CN¥993.28 Million
≈ $145.35 Million		 +11.29%
2017-12-31 CN¥892.48 Million
≈ $130.60 Million		 +2.23%
2016-12-31 CN¥873.05 Million
≈ $127.76 Million		 +14.00%
2015-12-31 CN¥765.84 Million
≈ $112.07 Million		 +13.22%
2014-12-31 CN¥676.42 Million
≈ $98.98 Million		 +19.52%
2013-12-31 CN¥565.92 Million
≈ $82.81 Million		 +117.57%
2012-12-31 CN¥260.11 Million
≈ $38.06 Million		 +29.37%
2011-12-31 CN¥201.07 Million
≈ $29.42 Million		 +19.18%
2010-12-31 CN¥168.71 Million
≈ $24.69 Million		 +0.20%
2009-12-31 CN¥168.37 Million
≈ $24.64 Million		 +121.88%
2008-12-31 CN¥75.88 Million
≈ $11.10 Million		 +6.82%
2007-12-31 CN¥71.04 Million
≈ $10.40 Million		 -30.14%
2006-12-31 CN¥101.70 Million
≈ $14.88 Million		 -17.81%
2005-12-31 CN¥123.73 Million
≈ $18.11 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 86475402900.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥864.75 Million 37.52%
Common Stock CN¥103.66 Million 4.50%
Other Comprehensive Income CN¥123.32 Million 5.35%
Other Components CN¥1.21 Billion 52.63%
Total Equity CN¥2.30 Billion 100.00%

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd ranked by their market capitalization.

Company Market Cap
Zhongyeda Electric Co Ltd
SHE:002441
 $824.73 Million
Yan Tai Shuang Ta Food Co Ltd
SHE:002481
 $825.02 Million
Heritage Insurance Hldgs Inc
NYSE:HRTG
 $825.07 Million
MCEWEN MINING INC.
F:US8
 $825.46 Million
Yieh Phui Enterprise Co Ltd
TW:2023
 $823.88 Million
Porch Group Inc
NASDAQ:PRCH
 $823.72 Million
Guangdong Greenway Technology Co Ltd
SHG:688345
 $823.70 Million
Nuh Cimento Sanayi AS
IS:NUHCM
 $823.60 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 2,357,553,851 to 2,304,567,412, a change of -52,986,439 (-2.2%).
  • Net income of 39,733,896 contributed positively to equity growth.
  • Dividend payments of 93,291,489 reduced retained earnings.
  • Other comprehensive income increased equity by 5,839,043.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥39.73 Million +1.72%
Dividends Paid CN¥93.29 Million -4.05%
Other Comprehensive Income CN¥5.84 Million +0.25%
Other Changes CN¥-5.27 Million -0.23%
Total Change CN¥- -2.25%

Book Value vs Market Value Analysis

This analysis compares Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 3.60x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 47.17x to 3.60x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2005-12-31 CN¥0.17 CN¥8.01 x
2006-12-31 CN¥0.14 CN¥8.01 x
2007-12-31 CN¥0.10 CN¥8.01 x
2008-12-31 CN¥0.10 CN¥8.01 x
2009-12-31 CN¥0.19 CN¥8.01 x
2010-12-31 CN¥0.20 CN¥8.01 x
2011-12-31 CN¥0.24 CN¥8.01 x
2012-12-31 CN¥0.31 CN¥8.01 x
2013-12-31 CN¥0.62 CN¥8.01 x
2014-12-31 CN¥0.71 CN¥8.01 x
2015-12-31 CN¥0.79 CN¥8.01 x
2016-12-31 CN¥0.91 CN¥8.01 x
2017-12-31 CN¥0.95 CN¥8.01 x
2018-12-31 CN¥1.06 CN¥8.01 x
2019-12-31 CN¥1.01 CN¥8.01 x
2020-12-31 CN¥2.03 CN¥8.01 x
2021-12-31 CN¥2.10 CN¥8.01 x
2022-12-31 CN¥2.19 CN¥8.01 x
2023-12-31 CN¥2.28 CN¥8.01 x
2024-12-31 CN¥2.22 CN¥8.01 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 1.72%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 5.60%
  • • Asset Turnover: 0.27x
  • • Equity Multiplier: 1.12x
  • Recent ROE (1.72%) is below the historical average (3.06%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2005 -25.18% -150.90% 0.14x 1.19x CN¥-42.41 Million
2006 -22.12% -111.47% 0.14x 1.46x CN¥-31.99 Million
2007 -42.18% -118.55% 0.19x 1.86x CN¥-36.56 Million
2008 -31.80% -73.15% 0.20x 2.15x CN¥-30.76 Million
2009 -5.39% -11.82% 0.21x 2.20x CN¥-20.89 Million
2010 2.64% 3.98% 0.30x 2.18x CN¥-10.24 Million
2011 18.13% 23.02% 0.37x 2.11x CN¥13.82 Million
2012 23.81% 22.86% 0.43x 2.41x CN¥30.84 Million
2013 16.37% 20.97% 0.56x 1.41x CN¥33.95 Million
2014 18.17% 25.11% 0.57x 1.27x CN¥53.16 Million
2015 17.43% 22.04% 0.57x 1.39x CN¥54.46 Million
2016 16.44% 22.30% 0.55x 1.33x CN¥54.35 Million
2017 8.63% 15.13% 0.43x 1.31x CN¥-11.95 Million
2018 11.42% 15.11% 0.51x 1.49x CN¥13.92 Million
2019 24.41% 22.09% 0.66x 1.68x CN¥134.21 Million
2020 8.19% 19.75% 0.33x 1.24x CN¥-36.43 Million
2021 9.73% 18.71% 0.41x 1.27x CN¥-6.00 Million
2022 6.11% 13.38% 0.35x 1.32x CN¥-87.71 Million
2023 4.61% 12.77% 0.30x 1.22x CN¥-127.13 Million
2024 1.72% 5.60% 0.27x 1.12x CN¥-190.72 Million

Industry Comparison

This section compares Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $4,691,234,838
  • Average return on equity (ROE) among peers: 6.16%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505) CN¥2.26 Billion -25.18% 0.09x $824.00 Million
Shenzhen Neptunus Bioengineering Co Ltd (000078) $903.62 Million 4.28% 2.45x $1.16 Billion
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $1.22 Billion 5.35% 1.27x $441.99 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $9.87 Billion 20.71% 0.25x $5.01 Billion
Livzon Pharmaceutical Group Inc (000513) $1.07 Billion 3.83% 0.46x $2.80 Billion
Wedge Industrial Co Ltd (000534) $1.15 Billion 11.42% 1.59x $3.04 Billion
Yunnan Baiyao Group Co Ltd (000538) $9.03 Billion 25.71% 0.43x $13.75 Billion
Hainan Haiyao Co Ltd (000566) $275.57 Million 17.28% 1.12x $947.33 Million
Tus Pharmaceutical Group Co Ltd (000590) $231.22 Million -38.13% 1.23x $389.67 Million
Northeast Pharmaceutical Group Co Ltd (000597) $4.29 Billion 2.31% 2.07x $1.03 Billion
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $18.87 Billion 8.83% 0.08x $3.32 Billion

About Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

SHG:688505 China Drug Manufacturers - Specialty & Generic
Market Cap
$824.00 Million
CN¥5.63 Billion CNY
Market Cap Rank
#10069 Global
#2875 in China
Share Price
CN¥8.01
Change (1 day)
-0.50%
52-Week Range
CN¥7.33 - CN¥11.12
All Time High
CN¥39.80
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of bio-pharmaceutical products in the People's Republic of China. It offers genetic engineering platform drugs, including Trop2-SN38 ADC that is in Phase III clinical trials for Triple-negative breast cancer; CD30-DM1 antibody-drug conjugate (ADC), which have complected Phase I clini… Read more